Gantenerumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. Gantenerumab targets and binds to beta amyloid then is removed through effector cell-mediated clearance. This reduces the level of beta amyloid in the brain. In Alzheimer's disease, beta amyloid accumulates in the brain and is a key component in plaque formation.

**Synonyms:** - GANTENERUMAB - Immunoglobulin G1, anti-(human 1-40-beta-amyloid/human 1-42-beta-amyloid) (human monoclonal gamma-1-chain), disulfide with human monoclonal kappa-chain, dimer - R-1450 - R04909832 - R1450